Company record · updated August 5, 2026
SpyGlass Pharma, Inc.: 5 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs January 16, 2026 to January 16, 2026.
5observations
1source filings
5verified rows
2026-01-16most recent as-of date
Source rails for this company: S-1 charter round (5).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-01-16 | Series D price per share | 2.3257 USD | — | VERIFIED | "Original Issue Price" defined for Series D | 000162828026002356 |
| 2026-01-16 | Series C-2 price per share | 1.7682 USD | — | VERIFIED | "Original Issue Price" defined for Series C-2 | 000162828026002356 |
| 2026-01-16 | Series C-1 price per share | 1.4145 USD | — | VERIFIED | "Original Issue Price" defined for Series C-1 | 000162828026002356 |
| 2026-01-16 | Series B price per share | 1.29 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000162828026002356 |
| 2026-01-16 | Series A price per share | 1.1 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000162828026002356 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.